Prothena Corporation plc filings document regulatory disclosures for an Irish clinical-stage biotechnology issuer with ordinary shares listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, business highlights, collaboration-related revenue, capital actions such as share repurchase authorization, and board or officer changes.
Proxy materials describe shareholder voting matters, executive compensation and board governance. The company’s filings also record ordinary-share capital matters, including shareholder approval of a capital reduction to create distributable reserves, along with exhibit-based press releases and Inline XBRL cover data.
Prothena Corp Public Ltd Co director Daniel G. Welch received a grant of stock options on Ordinary Shares covering 27,000 shares at an exercise price of $9.76 per share. These options vest 100% on the earlier of the first anniversary of the May 15, 2026 grant date or the company’s 2027 annual general meeting, assuming he continues to serve as a director through that date. Following this grant, his reported derivative holdings in this option series total 27,000 shares, and the filing shows no related sales or exercises.
PROTHENA CORP PUBLIC LTD CO director Dennis J. Selkoe received a grant of stock options for 27,000 shares. These options give the right to buy ordinary shares at an exercise price of $9.76 per share and are held as a direct ownership position.
The options will vest and become exercisable in full on the earlier of the first anniversary of the May 15, 2026 grant date or the day of the company’s 2027 annual general meeting, assuming he continues serving as a director through that date. After this grant, he holds options covering 27,000 shares.
Prothena Corp Public Ltd Co director Lars Ekman received a grant of stock options for 27,000 ordinary shares. The options have an exercise price of $9.76 per share and expire on May 15, 2036. They vest 100% on the earlier of the first anniversary of the grant date or the company’s 2027 annual general meeting, assuming he continues serving as a director until that vesting date. This is an equity compensation award rather than an open-market share purchase or sale.
PROTHENA CORP PUBLIC LTD CO director William H. Dunn Jr. received a grant of stock options covering 27,000 ordinary shares. The options have an exercise price of $9.76 per share, expire on May 15, 2036, and will vest 100% on the earlier of the first anniversary of the grant date or the company’s 2027 annual general meeting, assuming continuous board service.
PROTHENA CORP PUBLIC LTD CO director Shane Cooke received a grant of stock options covering 27,000 Ordinary Shares. The options carry an exercise price of $9.76 per share and expire on May 15, 2036. This is a compensation-related award, not an open-market purchase.
According to the terms, all 27,000 options will vest and become exercisable on the earlier of the first anniversary of the grant date or the day of the company’s 2027 annual general meeting, assuming he continues serving as a director until that vesting date.
PROTHENA CORP PUBLIC LTD CO director Richard T. Collier received a grant of stock options covering 27,000 ordinary shares. The options have an exercise price of $9.76 per share and expire on May 15, 2036. According to the award terms, all 27,000 options will vest and become exercisable on the earlier of the first anniversary of the May 15, 2026 grant date or the day of Prothena’s 2027 annual general meeting, provided he continues to serve as a director through that vesting date.
Prothena Corporation plc reported the results of its annual general meeting of shareholders. Shareholders re-elected Shane M. Cooke and Dennis J. Selkoe to the Board of Directors to serve until no later than the annual general meeting in 2029.
Shareholders also ratified, in a non-binding vote, the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and gave the Board, through its Audit Committee, binding authority to approve the auditor’s remuneration. In a separate non-binding advisory vote, shareholders approved the compensation of the Company’s named executive officers.
Prothena Corporation plc Schedule 13G/A shows Rubric Capital Management and related reporting person David Rosen hold 5,000,000 Ordinary Shares, representing 9.29% of the class. The filing states the share count basis is 53,832,982 Ordinary Shares outstanding as of March 2, 2026. The cover page reports the position is held with shared voting and shared dispositive power by the reporting persons. The statement identifies Rubric Capital Master Fund LP as a Rubric Fund with rights to dividends or sale proceeds on more than 5% of the class.
PROTHENA CORP PUBLIC LTD CO insider William P. Scully filed an initial ownership report as a ten percent owner of PRTA. He reports 736,000 ordinary shares held directly, plus 80,000 shares held indirectly through Manatee Equity Fund LLC and 52,000 shares held indirectly by his spouse. A footnote states he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Prothena Corp Public Ltd: William P. Scully filed an amended Schedule 13G/A reporting beneficial ownership of 5,378,846 Ordinary Shares, representing approximately 10.27% of the company's 52,353,237 shares outstanding as of April 30, 2026. The filing breaks ownership into positions with 793,000 shares of sole voting/dispositive power and 4,585,846 shares of shared voting/dispositive power.